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Acute organophosphate (OP) poisoning can be deadlier than any other type of chemical poisoning. So far, only a few 
cases have been described that include extensive neurological complications. We present an outstanding case of severe 
oral OP poisoning with intermediate syndrome developed on the fourth day after hospital admission. The clinical picture 
involved weakness of the proximal upper and lower limb muscles and several muscles supplied by motor cranial nerves, 
but, what is peculiar, the distal upper and lower limb muscles were also affected (forearms, hands, legs, and feet). To our 
knowledge, this is a unique presentation, as lower limb muscle weakness was reported only in the context of delayed 
polyneuropathy. Another remarkable feature was the involvement of six of the twelve cranial nerves, which makes this 
case of intermediate syndrome the first with such a spread of muscle weakness and provides new insights into the 
polymorphic clinical manifestations of acute OP poisoning.
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Since Clermont developed the first synthetic organic 
phosphorus anticholinesterase compound in 1854, more 
than 50,000 organophosphate substances (OPs) have been 
discovered. Acute OP poisoning is frequent in developing 
countries with easy access to anticholinesterase insecticides. 
The World Health Organization estimates that it causes 
more than 250,000 deaths every year (1). In Romania we 
deal with severe poisoning, prolonged hospitalisation and 
high cost for this category of patients. Of particular interest 
are the neurological complications that can occur. There 
are three phases of neurological manifestation: acute 
cholinergic crisis (ACC), intermediate syndrome (IMS), 
and organophosphate-induced delayed polyneuropathy 
(OPIDP), first reported by Wadia (2).
ACC develops in the first minutes to hours of OP 
poisoning. Due to the anticholinergic action, it affects 
muscarinic and nicotinic peripheral receptors and the central 
nervous system. The clinical picture is shaped by muscarinic 
and nicotinic symptoms (3). It involves the respiratory and 
cardiovascular system with rhinorrhoea, bronchospasm, 
bronchorrhoea, cough or severe respiratory distress, 
bradycardia and hypotension, gastrointestinal symptoms 
with nausea, vomiting, diarrhoea, and abdominal cramps, 
or neurological signs with fasciculation, muscle paralysis, 
dizziness, confusion, and seizures (4). These may be 
considered typical manifestations of ACC. More serious 
complications that can lead to death include coma and acute 
respiratory failure requiring mechanical intubation and 
ventilation (5).
OPIDP emerges within two to four weeks after exposure 
to OP insecticides and is characterised by lower limb muscle 
weakness, followed by progress toward upper limb muscles. 
After affecting the pyramidal tract, it leads to extrapyramidal 
symptoms characterised by spasticity or abnormal reflexes. 
Recovery can be complete in young patients, but 
neurological impairment may persist in certain cases (6).
IMS following acute OP poisoning is a complication 
with an incidence between 7.7 % and 84 % (7). This 
variability seems to be due to the great differences in 
defining IMS among studies. Generally, it appears two to 
four days after the cholinergic crisis in patients with severe 
and prolonged acetylcholinesterase (AChE) inhibition. The 
classic symptom defining IMS is weakness affecting the 
respiratory and limb girdle muscles, as well as muscles 
supplied by motor cranial nerves. (8) Uncommon 
presentations of IMS include extrapyramidal symptoms, 
bilateral vocal cord paralysis, or even all the three 
neurological phases in the same patient (9-10). All of these 
seem to reflect a pathophysiological dysfunction of the 
neuromuscular junction due to the accumulation of 
acetylcholine in the synaptic cleft. Other mechanisms 
include muscle necrosis, oxidative stress-related myopathy, 
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or persistent AChE inhibition (7). However, the 
pathophysiology underlying IMS is still not clear.
Here we present a case of severe IMS with weakness 
involving proximal and distal limb muscles and several 
muscles supplied by motor cranial nerves following acute 
ingestion of diazinon in a suicidal attempt of a 49-year-old 
woman. To our knowledge, this is the first report of IMS 
with such particular clinical presentation.
CASE REPORT
A 49-year-old woman ingested about 200 mL of 
diazinon in a suicide attempt. She had no prior medical 
history of suicidal thoughts or attempts. After approximately 
one hour from the ingestion, her family found her 
unconscious on the farm field. She had pulse but was 
unresponsive and sweating profusely, so the family took 
her to the local hospital. About one hour later, she received 
gastric lavage and activated charcoal and was then referred 
to our emergency department where she arrived two hours 
later with drowsiness, temporal and spatial disorientation, 
slur, generalised tremor, diaphoresis, cough, epigastric pain, 
nausea, and vomiting of white foam. Physical examination 
revealed hypotension (blood pressure 85/60 mmHg), 
bradycardia (heart rate 60-64 bpm), hypoxia (oxygen 
saturation was 88-90 % even on oxygen therapy delivering 
O2 at 4 L min
-1), midsized pupils, diaphoresis, hypersalivation, 
rhonchi in the inferior lung fields, and epigastric tenderness. 
The baseline measurement of serum butyrylcholinesterase 
(BuChE) was 281 U L-1 (normal values 4260-11250 U L-1). 
The chest X-ray (Figure 1) revealed a consolidation 
occupying the right inferior lung parenchyma.
Antidote treatment was started while the patient was in 
the emergency department, with two vials of 250 mg 
obidoxime and nine vials of 1 mg atropine with titration, 
both given intravenously (IV).
About two hours later, the patient was admitted to our 
toxicology department. On arrival, her blood pressure was 
110/70 mmHg and heart rate 114 bpm. She presented with 
dry skin, midsize pupils, persistent epigastric pain, nausea, 
and insecticide breath. Electrocardiogram (ECG) showed 
sinus tachycardia, and the full laboratory profile revealed 
leukocytosis, neutrophilia, increased C-reactive protein 
(CRP), fibrinogen, and abnormal urine findings due to the 
urinary tract infection with E. coli.
We continued antidote treatment with atropine and 
adjusted the doses to the signs of atropinisation; we started 
with one vial every 2 h for one day, then changed to every 
4 h for the next three days, and finally to every 6 h for the 
next five days, after which atropine treatment was stopped. 
IV obidoxime was also continued for 72 h from admission 
to the toxicology department, and two units of fresh frozen 
plasma (FFP) were administered in the first two days. Serum 
BuChE was monitored regularly (Figure 2). The patient’s 
general status improved with antidote treatment. Her 
haemodynamics was stable, oxygen saturation normal (no 
artificial ventilation was needed), pupils midsize, skin dry, 
and she was conscious and oriented. The cholinergic and 
digestive symptoms gradually receded and only a mild 
cough persisted. In spite of the atropine treatment, however, 
on the fourth day of admission to our toxicology department, 
the patient developed myoclonic twitches of the jaw and 
tremor of the head and arms. She complained of a 
generalised weakness and difficulty moving the limbs, 
standing, staying seated, and breathing due to respiratory 
muscle weakness. Neurological examination revealed 
myasthenia gravis due to OP poisoning. Her sensation was 
unaltered but with diminished tendon reflexes. Head 
computed tomography with contrast showed diffuse cerebral 
oedema (Figure 3). Lumbar puncture was normal. The 
treatment of the cerebral oedema started with a loop diuretic, 
but the patient’s neurological status continued to decline. 
The next day she had the Glasgow Coma Score of 11, 
bilateral ptosis, and difficulty opening and closing her 
mouth. She could not chew, raise eyebrows, or smile. 
Clinical signs and symptoms of bulbar palsy were also 
present, along with dysphagia, hoarse voice, and inability 
to shrug or turn the head. Secretions from the respiratory 
tract were removed with bronchial endoscopy. Arterial 
blood gases were within the normal range. Electromyography 
was not performed. All these clinical, neurological, and 
radiological findings pointed to the diagnosis of an atypical 
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Figure 1 X-ray of the patient poisoned with diazinon on admission
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Further confirmation of the diagnosis came with low 
serum BuChE, which is a common finding among patients 
poisoned with OPs (13). Several studies found that the 
severity of poisoning and the need for intubation rose with 
lower plasma or serum levels (14-15). However, whether 
the level of serum cholinesterase correlates with the severity 
of poisoning is still a matter of debate.
In our case, serum BuChE was severely depressed, with 
only slight fluctuations throughout hospitalisation, despite 
optimal atropine and oxime therapy and the administration 
of two units of FFP over the first two days of admission to 
our toxicology department. This finding is consistent with 
the report by Pazooki et al. (16). In contrast, a prospective 
study (17) with 33 cases of OP poisoning, reported that nine 
patients treated only with atropine + pralidoxime developed 
IMS, while no IMS was observed in those who received 
atropine + pralidoxime + FFP. BuChE plasma levels were 
similar between the two groups on admission to the hospital, 
but in the FFP-treated group they increased by 461 U L-1 
with every two bags of plasma given.
BuChE provided with plasma might play a role in 
sequestrating OPs in the circulation and stop further AChE 
inhibition. This may become extremely important when 
AChE activity is extremely low. In addition, FFP provides 
other important molecules, such as esterases and proteases, 
which may counteract the OP effects. How successfully will 
depend on the type of OP pesticides (18). Further research 
is therefore needed to better understand the effects of BuChE 
on the central nervous system (17).
IMS appears within the first 24 to 96 h of OP ingestion 
and can last up to six days. Recent studies, however, have 
shown that IMS may also occur outside this time frame, 
even after acute cholinergic crisis seems to have been 
resolved. Our patient’s symptoms are the case in point: they 
IMS due to severe OP poisoning. We introduced treatment 
with mannitol, group B vitamins, and haemoglobin glutamer 
(Actovegin) and kept the patient under close observation. 
To address respiratory and urinary tract infection we also 
introduced antibiotic treatment according to her antibiogram.
The patient’s neurological status improved in the days 
that followed. She fully recovered from muscle weakness, 
but the signs of facial nerve palsy remained. She was 
discharged after 14 days in hospital and had been followed 
up periodically for the next year.
DISCUSSION
The clinical features and prognosis in OP poisoning 
depend on the type of pesticide, dose, route of administration, 
and the moment when treatment is initiated. With our 
patient, the culprit pesticide was a diethyl compound 
diazinon, the most common category of pesticide nowadays 
(11). A recent study by Peter et al. (12) showed that the 
diethyl group was associated with later onset and less severe 
symptoms than the dimethyl group of OPs. Also, the 
incidence of the IMS and the need for tracheostomy or 
intubation were significantly lower with the diethyl 
compounds. The diethyl group contains fat-soluble 
organophosphates that remain in the circulation in low 
levels and may persist for a longer period of time.
After ingestion, diazinon causes a rise in acetylcholine 
concentration with subsequent stimulation of the muscarinic 
and nicotinic receptors shaping the acute cholinergic 
syndrome (11). On admission, our patient had the classic 
hallmarks of this syndrome with hypotension, bradycardia, 
cough, nausea, vomiting, and abdominal pain due to 
muscarinic effects, accompanied by nicotinic manifestations.
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Figure 2 Serum cholinesterase levels in the patient poisoned with diazinon over the 14 days of hospitalisation
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atypical manifestations with a relapse of acute cholinergic 
symptoms at the beginning of IMS. In our case, we noticed 
concomitant development of fasciculation in the jaw 
muscles and symptoms of IMS. This situation has already 
been reported in literature; De Bleecker et al. (14) observed 
that out of eight patients with IMS, six developed 
cholinergic symptoms, such as fasciculation, bradycardia, 
diarrhoea, sweating, lacrimation, and increased salivary and 
bronchial secretion.
CONCLUSION
Early recognition of muscle weakness before major 
complications appear can save lives. Our case stands out 
with an atypical IMS.
First, it is quite uncommon (although not unheard of) 
that acute cholinergic symptoms such as muscle fasciculation 
should appear at this stage.
Second, muscle weakness spread to the distal limbs, 
which has only been encountered in delayed polyneuropathy, 
bearing the risk of becoming a chronic condition. 
Fortunately, this symptom regressed within several days 
with the accompanying clinical manifestations.
Third, six of the twelve cranial nerves were involved, 
which makes this case of IMS the first with such an large 
extent of muscle weakness.
All these new findings in our case witness to the 
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seemed to have improved, but 72 h after admission, she 
developed a weakness in several muscle groups. Our 
findings correspond to the clinical features of IMS first 
described in 1987 (19) as weakness of the neck flexors, 
respiratory, proximal limb muscles, and certain muscles 
supplied by motor cranial nerves.
One of the most important complications, however, is 
the respiratory failure requiring intubation and mechanical 
ventilation (20). It can appear in 24-66 % of patients and 
directly correlates with the severity of poisoning. Other risk 
factors for intubation/ventilation include pneumonia, acute 
pulmonary oedema, or cardiovascular collapse (21). Our 
patient remained stable (under constant monitoring), even 
though she was severely poisoned and developed 
pneumonia.
To the best of our knowledge, this is the first case 
reporting a distal limb muscle weakness. Our patient was 
unable to extend, flex or lift up her forearms, hands, legs, 
and feet. She was incapable to stand, sit, or walk. Her tendon 
reflexes were slower but the sensation was preserved. The 
weakness of the distal limbs was reported earlier only in 
the context of OPIDP, which develops two to three weeks 
after OPs poisoning. The clinical picture of OPIDP includes 
weakness and numbness in the lower limbs, followed by 
progression toward the upper limbs (6). Symptoms may 
last for up to two years, but recovery can be complete, 
especially in young patients. In our case, the symptoms 
regressed to full resolution until discharge from the hospital.
Weakness in the muscle groups supplied by the 3rd 
(bilateral ptosis), 5th (inability to close the mouth or to 
chew), and 7th (inability to smile and raise eyebrows) motor 
cranial nerve as well as the bulbar syndrome in our patient 
clearly point to multiple cranial nerve involvement. 
Literature does report that IMS may affect motor cranial 
nerves but not to such an extent (19, 22). In a study which 
evaluated IMS in 21 patients (23), 17 had weakness in the 
muscles supplied by motor cranial nerves and three had 
Figure 3 CT scan shows a discrete supra-tentorial loss of grey-white matter differentiation, with the effacement of the cerebral sulci 
and obliteration of supraselar and ambiens cisterns. There are no signs of uncal herniation
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Novi uvidi u intermedijarni sindrom uzrokovan trovanjem organofosfatnim pesticidom
Akutno trovanje organofosfatima (OP) može biti smrtonosnije od bilo koje druge vrste trovanja kemikalijama. Dosada 
je opisano tek nekoliko slučajeva s neurološkim komplikacijama širokih razmjera. Ovdje donosimo prikaz jednog iznimnno 
teškog slučaja trovanja pacijentice diazinonom, u koje se intermedijarni sindrom javio četvrtoga dana hospitalizacije. 
Njezina klinička slika obuhvaćala je slabost u pojedinim mišićima proksimalnih dijelova gornjih udova povezanih s 
motornim kranijalnim živcima, ali ono što je neobično bila je slabost mišića u distalnim dijelovima donjih udova. Koliko 
znamo, to je jedinstven takav slučaj, s obzirom na to da je slabost u mišićima donjih udova opisana samo u kontekstu 
kasne polineuropatije. Uz to, ovaj se slučaj intermedijarnog sindroma ističe i dosad nezabilježenom zahvaćenošću šest 
od dvanaest kranijalnih živaca. Time je dobiven novi uvid u polimorfnu narav kliničkih manifestacija akutnog trovanja 
organofosfatima.
KLJUČNE RIJEČI: kolinesteraze; mijastenija; motorni kranijalni živci; slabost mišića donjih udova
